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Abstract 
Background: In 2011, Uganda’s Ministry of Health switched policy from presumptive treatment of malaria to recom-
mending parasitological diagnosis prior to treatment, resulting in an expansion of diagnostic services at all levels of 
public health facilities including hospitals. Despite this change, anti-malarial drugs are often prescribed even when 
test results are negative. Presented is data on anti-malarial prescription practices among hospitalized children who 
underwent diagnostic testing after adoption of new treatment guidelines.
Methods: Anti-malarial prescription practices were collected as part of an inpatient malaria surveillance program 
generating high quality data among children admitted for any reason at government hospitals in six districts. A 
standardized medical record form was used to collect detailed patient information including presenting symptoms 
and signs, laboratory test results, admission and final diagnoses, treatments administered, and final outcome upon 
discharge.
Results: Between July 2011 and December 2013, 58,095 children were admitted to the six hospitals (hospital range 
3294–20,426).A total of 56,282 (96.9 %) patients were tested for malaria, of which 26,072 (46.3 %) tested positive 
(hospital range 5.9–57.3 %). Among those testing positive, only 84 (0.3 %) were first tested after admission and 295 of 
30,389 (1.0 %) patients who tested negative at admission later tested positive. Of 30,210 children with only negative 
test results, 11,977 (39.6 %) were prescribed an anti-malarial (hospital range 14.5–53.6 %). The proportion of children 
with a negative test result who were prescribed an anti-malarial fluctuated over time and did not show a significant 
trend at any site with the exception of one hospital where a steady decline was observed. Among those with only 
negative test results, children 6–12 months of age (aOR 3.78; p < 0.001) and those greater than 12 months of age 
(aOR 4.89; p < 0.001) were more likely to be prescribed an anti-malarial compared to children less than 6 months of 
age. Children with findings suggestive of severe malaria were also more likely to be prescribed an anti-malarial after a 
negative test result (aOR 1.98; p < 0.001).
Conclusions: Despite high testing rates for malaria at all sites, prescription of anti-malarials to patients with negative 
test results remained high, with the exception of one site where a steady decline occurred.
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Background
Malaria is reported by the Ministry of Health’s Health 
Management Information System to be the leading cause 
of morbidity and mortality in Uganda, accounting for 
30–50 % of outpatient visits, 35 % of hospital admissions, 
and 9–14 % of hospital deaths [1]. More recent estimates 
from the World Health Organization (WHO) listed 
Uganda as having one of the highest malaria burdens in 
the world with an estimated 10,338,093 probable and 
confirmed cases, 592,264 inpatient malaria cases, and 
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6585 inpatient deaths in 2012 [2]. For children admitted 
to the hospital with malaria, case management including 
early diagnosis and prompt, effective treatment is a key 
strategy for minimizing deaths [3].
In 2010, WHO introduced two major changes to treat-
ment guidelines for malaria case management. First was 
the replacement of presumptive treatment with parasi-
tological diagnosis whenever possible, and second was 
the replacement of intravenous quinine with intravenous 
artesunate as first-line treatment for severe malaria [4]. 
The Uganda Ministry of Health adopted both changes in 
2011 [5]. The new emphasis on parasitological diagnosis 
does not distinguish between patients with uncompli-
cated and severe malaria. However, due to the life-threat-
ening nature of severe malaria, the WHO emphasizes 
treatment should not be delayed in the interest of obtain-
ing a test result [6]. Parasitological confirmation of 
malaria is essential for targeting anti-malarial treatment 
to appropriate patients [7, 8]. Advantages of targeted 
treatment include minimizing unnecessary use of drugs, 
avoiding selection of drug resistance, and reducing expo-
sure of patients to adverse events associated with unnec-
essary anti-malarial drug treatments [9–11]. In the case 
of severe malaria, parasitological confirmation of disease 
minimizes misclassification of other severe febrile ill-
nesses as malaria [6].
Despite changes in policy recommendations and 
reported benefits, reports indicate that anti-malarial 
therapy continues to be prescribed to children even fol-
lowing a negative malaria test result [12]. Utilizing data 
collected from an enhanced inpatient malaria surveil-
lance system from July 2011 through December 2013, 
presented are results on anti-malarial prescription prac-
tices among children with test results admitted to six 
government hospitals in Uganda from areas of varying 
malaria endemicity. To improve the understanding of 
prescription practices, presented to are factors associated 
with the prescription of anti-malarials to children with 
negative malaria test results.
Methods
Uganda malaria surveillance project (UMSP)
Between April 2010 and June 2011, the Uganda Malaria 
Surveillance Project (UMSP) in collaboration with the 
National Malaria Control Programme (NMCP) estab-
lished an inpatient malaria surveillance system at pub-
lic hospitals in six districts—Tororo, Jinja, Kanungu, 
Mubende, Apac and Kabale—representing distinct geog-
raphy and malaria transmission intensity (Fig. 1). UMSP 
has also been supporting outpatient malaria sentinel 
surveillance programme in these six districts since 2006 
[13]. Tororo, Kambuga (Kanungu District), and Apac 
are general hospitals providing basic inpatient health 
services whereas Jinja and Kabale are regional referral 
hospitals offering specialist medical and surgical services. 
Mubende was elevated to a regional referral hospital in 
2012.
A standardized individual medical record form (MRF) 
was developed by UMSP in consultation with the NMCP. 
The MRF collects detailed patient information including 
presenting symptoms and signs, laboratory test results, 
admission and final diagnoses, treatments administered, 
and final outcome upon discharge. The MRF uses check 
boxes to minimize transcription errors, and incorporates 
Integrated Management of Childhood Illnesses (IMCI) 
terminology for signs and symptoms, a standard frame-
work familiar to most clinicians in Uganda. UMSP was 
responsible for ensuring that MRFs were available at all 
study sites.
Training
Upon initiation of the inpatient malaria surveillance sys-
tem, training was provided to the clinical staff on the 
use of the new MRF, the importance of good medical 
record keeping, the use of data to improve the quality 
of services, and proper case management of uncompli-
cated and severe malaria. Case management training was 
conducted with all clinicians during a 1-day session that 
was repeated on a second day to maximize the propor-
tion of staff who received training. Through lectures and 
the distribution of job aides, case management training 
focused on the importance of malaria diagnosis based on 
parasitological confirmation, the use of quinine for severe 
malaria (prior to the policy change recommending intra-
venous artesunate), and strategies aimed at streamlining 
patient flow within the hospital with the goal of reduc-
ing wait time. Hospital staff were also trained to test all 
paediatric admissions for malaria as a component of the 
programme’s goal of measuring the test positivity rate of 
all inpatients. This training included political and admin-
istrative district leadership, hospital administration, and 
hospital staff.
Prior to start of the surveillance programme a labo-
ratory staff at respective hospitals underwent a 3-day 
refresher course in malaria microscopy. The curricu-
lum and training materials were developed by a team of 
laboratory experts from UMSP, Ministry of Health, and 
Central Public Health Laboratories as well as district 
laboratory focal persons, the details of which have been 
previously published [14]. Training at all sites was fol-
lowed by a pilot period to identify and address additional 
barriers to collecting high quality data. Sites were allowed 
to proceed only when the proportion of paediatric admis-
sions tested for malaria was greater than 90 %. For most 
sites, this occurred approximately 2  months after the 
start of the pilot.
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Patient care
Patient care in all hospitals except Jinja was provided by 
clinical officers (diploma level training in medicine) and 
nurses. A clinical officer made the decision for admis-
sion after the child was initially seen in the outpatient 
department. All admitted children had an MRF com-
pleted by the clinical officer, documenting the child’s 
presenting symptoms and signs, initial diagnoses, and 
treatments prescribed. For most hospitalized children, 
nurses provided routine care. For critically ill children, a 
clinical officer or a medical doctor was often consulted. 
Mubende Hospital also had a consultant paediatrician 
who provided care in the paediatric ward.
Jinja Hospital staffing capacity was different in com-
parison to the other five hospitals. In addition to clini-
cal officers, intern doctors were responsible for making 
admission decisions and reviewing admitted children on 
a daily basis. A team of three consultant paediatricians 
supervised the interns, reviewed children in the unit, and 
provided daily support including weekends. In all hos-
pitals, nurses made the admission decision if a clinician 
was not available.
Most children admitted at all six hospitals were severely 
ill. Occasionally children with uncomplicated disease 
were admitted. Possible reasons for admitting children 
with uncomplicated disease states include, existence of 
Fig. 1 Hospital locations overlying map of Uganda with modelled parasite rates. The colours are PfPR in the over 2 and up to 10 year age group 
from the MAP 2010 data set [38]
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co morbid states warranting admission, self-request for 
hospitalization, and lack of oral medicines required to 
treat uncomplicated illness warranting admission for 
treatment with intravenous medications.
Quality assurance
Following the initiation of surveillance at the six public 
hospitals, supportive supervision visits were conducted 
by the UMSP surveillance team consisting of a physician, 
laboratory supervisor, and data supervisor. The visits 
were initially conducted every 2–3 months and were later 
spaced out to every 4–6  months by 2013. During each 
visit data quality was assessed and feedback provided. 
Additional data dissemination workshops were held bian-
nually at each site, and included presentations on data 
quality, key malaria indicators, morbidity and mortality 
trends, and treatment practices. Administrative issues, 
potentially affecting performance at each site, were also 
discussed at the workshops. Continued support to labo-
ratories, including external quality control, was provided 
by UMSP and the district health office to ensure adequate 
staffing, supply of reagents and slides, and adherence to 
high standards of malaria microscopy. The quality con-
trol system used expert microscopists to re-read 50 ran-
domly selected slides and any hospital microscopist with 
less than 90 % concordance was re-trained. Quality con-
trol was carried out monthly at the beginning of the pro-
ject, but changed to every 6 months after the UMSP team 
felt that quality was being maintained.
Data management and statistical analyses
MRFs of discharged patients were collected on a daily 
basis and entered into an Access database (Microsoft 
Corporation, Redmond, WA, USA) and transmitted 
to a central database located in Kampala, Uganda on a 
monthly basis. Prior to being uploaded to a secure server, 
data were checked for errors. Stata version 12 was used 
for data analysis (Stata Corp., College Station, TX, USA).
All children (age <14  years) admitted to the six hos-
pitals from July 2011 through December 2013 were 
included in the analysis. The following malaria case man-
agement indicators were examined: (1) proportion of 
admitted children with any malaria test result performed; 
positive or negative, (2) proportion of children prescribed 
anti-malarial drugs, stratified by positive or negative test 
result, and (3) type of anti-malarial drug prescribed, 
stratified by positive or negative result. A patient was 
reported to have a positive malaria test if any test result 
[presence of asexual parasitaemia by light microscopy or 
positive rapid diagnostic test (RDT)] was positive dur-
ing hospitalization. A patient was reported to have only 
negative malaria test results if all test results were nega-
tive during hospitalization. A patient was defined as hav-
ing complicated malaria, if had a positive malaria test 
result and presented with symptoms or signs consistent 
with WHO definition of severe malaria or had danger 
signs warranting intravenous treatment [3]. If a patient 
received more than one anti-malarial drug while in the 
hospital they were placed in a single category based on 
the following hierarchy (informed by current national 
treatment guidelines): (1) intravenous artesunate, (2) 
intravenous quinine, (3) intramuscular artemether, (4) 
rectal artesunate, (5) oral artemether–lumefantrine, (6) 
oral quinine, (7) oral artesunate, (8) oral sulfadoxine–
pyrimethamine, and (9) oral chloroquine. A regression 
model using the Generalized Estimating Equations (GEE) 
approach was used to estimate associations between 
covariates of interest and the odds of being prescribed an 
anti-malarial among children with negative malaria test 
results, while accounting for repeated measures on the 
date of admission. Covariates considered included the 
hospital, age, presence of fever (either reported or objec-
tively measured as ≥38.0  °C), and signs or symptoms of 
complicated malaria (history of or witnessed convul-
sions, altered consciousness, tea coloured urine, jaun-
dice, unconsciousness, lethargy, inability to sit, or severe 
pallor).
Results
Overview of malaria diagnostic testing
A total of 58,095 children were admitted to the six hospi-
tals over the 30-month period. Total number of hospital 
admissions during this period was highest in Jinja (total 
20,426; monthly mean 680) and lowest in Kambuga (total 
3294; monthly mean 110). Fever was reported or docu-
mented in 91.6 % of patients and 49.0 % of patients had 
signs or symptoms suggestive of complicated malaria. 
The proportion of children tested for malaria was greater 
than 95 % at all hospitals and testing rates were consist-
ently high throughout the study period. Among 56,282 
patients tested for malaria, 26,072 (46.3  %) tested posi-
tive, ranging from 5.9  % in Kabale to 57.3  % in Apac 
(Table  1). Among those tested for malaria, final test 
results were based on a RDT for only 1601 patients 
(2.8 %), with the remainder based on microscopy. Among 
patients with final test results based on a RDT, 88.8  % 
were from a single hospital (Tororo). Among patients 
who tested positive for malaria, only 84 (0.3 %) were first 
tested after admission (50 within 1  day of admission). 
Among 30,389 patients who tested negative at admission, 
295 (1.1  %) tested positive after an initial negative test 
(109 within 1 day of admission) (Fig. 2).
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Anti‑malarial prescription practices among children 
with positive test results
Greater than 94 % of children with any positive malaria 
test result were prescribed an anti-malarial in all hospi-
tals, with the exception of Kabale hospital (90.1  %), the 
site with the lowest malaria test positivity rate. In Kabale, 
the practice of prescribing anti-malarials to patients with 
any positive malaria test decreased significantly in 2013 
compared to the previous 18  months (82.6 vs 94.8  %; 
p  =  0.003). In all 22 cases where no anti-malarial was 
prescribed despite a positive test in Kabale, the positive 
test was performed at the time of admission.
Among children with a positive malaria test result 
who were prescribed an anti-malarial, intravenous qui-
nine was prescribed most frequently (81.9  %), ranging 
from 52.5 % in Kabale to 87.8 % in Tororo (Table 2). The 
next most common anti-malarials prescribed were intra-
venous artesunate (13.2  %), intramuscular artemether 
(3.0  %), oral artemether-lumefantrine (1.4  %), and oral 
quinine (0.4 %). Intravenous artesunate was prescribed to 
fewer than 5 % of children who were prescribed an anti-
malarial after a positive malaria test result until April 
2013, when the proportion began increasing (Fig.  3). 
The increase in IV artesunate was not sustained at Apac, 
Tororo, and Mubende where a decline was observed 
during the final months of 2013. Overall, in the latter 
half of 2013, 35.2  % of children with a positive malaria 
test receiving an anti-malarial were prescribed intra-
venous artesunate. During this same 6-month period, 
the proportion of these children who were prescribed 
intravenous artesunate varied widely by health facility 
with Kabale (100  %) having the highest proportion, fol-
lowed by Jinja (67.3 %), Kambuga (43.2 %), Apac (32.6 %), 
Tororo (26.2 %), and Mubende (4.2 %).
Anti‑malarial prescription practices among children 
with negative test results
Among the 30,210 children with only negative malaria 
test results, 11,977 (39.6  %) were prescribed any 
anti-malarial drugs, ranging from 14.5  % in Kabale to 
53.6  % in Jinja and Mubende (Table  1). Anti-malarial 
treatment practices differed based on malaria test results. 
Compared to children with any positive test result, chil-
dren with only negative test results were less likely to be 
prescribed intravenous quinine (81.9 vs 74.7 %, p < 0.001) 
or intravenous artesunate (13.2 vs 10.1 %; p < 0.001); and 
more likely to be prescribed intramuscular artemether 
(2.9 vs 5.4  %; p  <  0.001) and oral artemether–lumefan-
trine (1.3 vs 7.5 %; p < 0.001).
The proportion of children with only negative malaria 
test results who were prescribed any anti-malarial drug 
during the first 3  months of the study period varied 
from 13.9  % in Tororo to 61.8  % in Mubende. During 
the course of the study, trends in prescription practices 
among children with only negative malaria test results 
showed a steady decline in Kabale, where 165 of 334 
(49.4 %) children were prescribed any anti-malarial drug 
during the first 3 months of the study, decreasing to only 
4 of 337 (1.2 %) children during the last 3 months of the 
study. However, the other five hospitals showed greater 
fluctuation and no significant trend in the practice of 
prescribing any anti-malarial drug to children with only 
negative malaria test results (Fig. 4).
Predictors of anti‑malarial prescription to children 
with only negative results
Associations between covariates of interest including the 
hospital, age, the presence of fever, and clinical findings 
suggestive of complicated malaria with the odds prescrib-
ing any anti-malarial drugs to children with only negative 
malaria test results are presented in Table 3. The hospi-
tal was strongly associated with the odds of anti-malarial 
prescription among children with only negative malaria 
test results. Compared to the hospital (Kabale) with 
the lowest frequency of prescribing anti-malarial drugs 
(14.5 %), the adjusted odds ratio (aOR) of prescribing an 
anti-malarial using multivariate analysis ranged from 1.77 
(p < 0.001) in Tororo to 7.63 (p < 0.001) in Jinja. Age was 
Table 1 Malaria testing and treatment practices among children admitted to six hospitals: July 2011 to December 2013
Hospital Total  
admissions
Tested for malaria  
(% total)
Test positivity  
rate (%)
Proportion prescribed an  
anti‑malarial drug (%)
Positive test result Negative test result
Tororo 13,538 12,962 (95.7) 57.3 7291/7421 (98.2) 1154/5541 (20.8)
Jinja 20,426 19,800 (96.9) 46.6 9085/9229 (98.4) 5661/10,571 (53.6)
Kambuga 3294 3248 (98.6) 32.4 998/1052 (94.9) 877/2196 (39.9)
Mubende 10,030 9751 (97.2) 43.4 4077/4234 (96.3) 2958/5517 (53.6)
Apac 6946 6755 (97.3) 57.9 3832/3914 (97.9) 814/2841 (28.7)
Kabale 3861 3766 (97.5) 5.9 200/222 (90.1) 513/3544 (14.5)
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also strongly associated with the odds of anti-malarial 
prescription to children with only negative malaria test 
results, as children 6–12  months (aOR 3.78, p  <  0.001) 
and greater than 12  months (aOR4.89, p  <  0.001) were 
more likely than children under 6  months of age to be 
prescribed an anti-malarial. Selected symptoms and 
58,095 total admissions 
56,082 tested at admission 2,013 not tested at admission 
25,693 tested posive at admission 
          24,494 microscopy 
            1,199 RDT 
30,389 tested negave at admission 
          29,987 microscopy 
               402 RDT 
31 tested posive later day of admission 
          31 microscopy 
78 tested posive 1 day aer admission 
          73 microscopy 
            5 RDT 
72 tested posive 2 days aer admission 
          71 microscopy 
            1 RDT 
37 tested posive 3 days aer admission 
          35 microscopy 
            2 RDT 
77 tested posive > 3 days aer admission 
          70 microscopy 
            7 RDT 
4 tested negave later day of admission 
          4 microscopy 
7 tested posive later day of admission 
          7 microscopy 
40 tested negave 1 day aer admission 
          38 microscopy 
             2 RDT 
43 tested posive 1 day aer admission 
          35 microscopy 
             8 RDT 
27 tested negave 2 days aer admission 
          26 microscopy 
             1 RDT 
11 tested posive 2 days aer admission 
          11 microscopy 
20 tested negave 3 days aer admission 
          20 microscopy 
13 tested posive 3 days aer admission 
          12 microscopy 
             1 RDT 
25 tested negave > 3 days aer admission 
          25 microscopy 
10 tested posive > 3 days aer admission 
          7 microscopy 
          3 RDT 
 26,072 any posive test result (24,846 microscopy, 1226 RDT) 
30,210 only negave test results  
1,813 never tested 
Fig. 2 Timing and method of malaria diagnostic testing during hospitalization. Only the first positive and negative test results presented
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physical examination findings were also associated with 
the odds of being prescribed an anti-malarial drug among 
children with only negative malaria test results. Children 
who had fever (as reported by the parent or measured at 
admission) had a higher odds of being prescribed an anti-
malarial compared to those with no fever (43.8 vs 12.2 %, 
aOR 5.43, p < 0.001). Children with symptoms and physi-
cal exam findings suggestive of complicated malaria had 
a higher odds of being prescribed for an anti-malarial 
(49.7 vs 29.2 %, aOR 1.98, p < 0.001).
Discussion
Demonstration of the presence of malaria parasites prior 
to treatment with appropriate anti-malarial medicine 
has recently been adopted as a global standard of care 
for malaria case management [15]. Proper diagnosis 
and treatment of malaria is especially crucial in Ugan-
dan hospitals as a majority of admitted children have 
fever as well as other symptoms and signs suggestive of 
complicated malaria. Presented is data on malaria pre-
scription practices from a sentinel site programme, 
where malaria diagnostic capacity is supported, clini-
cians receive malaria case management training, and the 
testing of each admitted child for malaria is encouraged 
and subject to external quality assurance. Presented data 
are notable for high rates of malaria diagnostic testing, 
a recent shift from the prescription of intravenous qui-
nine to intravenous artesunate for malaria, and frequent 
prescription of anti-malarials to children with a negative 
malaria test result. The analysis also reveals factors asso-
ciated with the prescription of anti-malarials to children 
with only negative malaria test results, findings which 
will be critical to designing programmes to improve 
provider compliance with malaria case management 
guidelines.
Table 2 Anti-malarial drugs prescribed to hospitalized children with positive malaria test results
Anti‑malarial type Hospital
Tororo  
(n = 7291) (%)
Jinja  
(n = 9085) (%)
Kambuga  
(n = 998) (%)
Mubende  
(n = 4077) (%)
Apac  
(n = 3832) (%)
Kabale  
(N = 200) (%)
IV quinine 6404 (87.8) 7162 (78.8) 842 (84.4) 3513 (86.2) 2842 (74.2) 105 (52.5)
IV artesunate 457 (6.3) 1578 (17.4) 112 (11.2) 239 (5.9) 915 (23.9) 66 (33.3)
IM artemether 336 (4.6) 262 (2.9) 10 (1.0) 141 (3.5) 5 (0.1) 7 (3.5)
Oral artemether– 
lumefantrine
87 (1.2) 59 (0.6) 12 (1.2) 125 (3.1) 55 (1.4) 17 (8.5)
Oral quinine 3 (0.04) 16 (0.2) 18 (1.8) 54 (1.3) 8 (0.2) 3 (1.5)
Rectal artesunate 2 (0.03) 1 (0.01) 4 (0.4) 2 (0.04) 7 (0.2) 1 (0.5)
Oral sulfadoxine–
pyrimethamine
1 (0.01) 4 (0.04) 0 2 (0.04) 0 1 (0.5)
Oral artesunate 1 (0.01) 3 (0.03) 0 0 0 0
Oral chloroquine 0 0 0 1 (0.02) 0 0
Fig. 3 Temporal trends in the proportion of children prescribed intra-
venous artesunate among those with any positive malaria test result 
who were prescribed any anti-malarial stratified by study site
Fig. 4 Temporal trends in the proportion of children prescribed anti-
malarial drugs among those with only negative malaria test results 
stratified by study site
Page 8 of 10Sserwanga et al. Malar J  (2015) 14:331 
Through sustained supervision, adopting a goal of 
universal testing, and buffering of the supply chain for 
essential materials required for malaria diagnostic test-
ing, testing rates over 95 % among children admitted to 
the six public hospitals were achieved. Among children 
with positive tests results, intravenous quinine was the 
most commonly prescribed anti-malarial. At the start of 
the programme, intravenous artesunate, recommended 
by WHO and the Ministry of Health as first line treat-
ment for complicated malaria in children, was rarely pre-
scribed. However, in the latter half of 2013, a dramatic 
increase in prescription rates of intravenous artesunate 
was noted across all sites, though this was not sustained 
at some sites in subsequent months. The rise in prescrip-
tion rates of intravenous artesunate corresponded to 
the actual implementation of the policy change adopted 
2 years earlier in Uganda. The rapid decline in prescrip-
tion rates observed at two sites following the initial surge 
was attributed to failed reacquisition of intravenous 
artesunate. These difficulties highlight the challenges of 
implementing and sustaining new policies in resource-
limited settlings like Uganda.
Among children with only negative malaria test results, 
data showed high rates of prescription of anti-malarials, 
results comparable to those reported in a similar set-
ting in Tanzania prior to the global recommendation 
for universal diagnostic testing for malaria [12]. Despite 
training efforts, only one hospital, located in the lowest 
transmission setting, demonstrated a decline in this prac-
tice. A case for the presumptive treatment in endemic 
areas in the absence of laboratory confirmation has been 
argued (especially in the setting of unreliable laboratory 
diagnosis) [16–20], however this argument becomes less 
acceptable in low transmission settings where the posi-
tive predictive value of clinical diagnosis is low [8]. Fur-
thermore, the practice of withholding anti-malarials from 
children after a negative malaria test has been shown 
to be safe and effective in a variety of transmission set-
tings, including hospitalized children [20–23]. Indeed, in 
our study over 96 % of patients were tested at admission 
and only 1 % of those who tested negative at admission 
went on to have a positive test. Additionally, prescrip-
tion of anti-malarials to hospitalized children with nega-
tive test results has been associated with increased risk of 
mortality, a fact attributed to mismanagement of the true 
underlying (non-malarial) cause of illness [24–26]. Con-
trary to expectations, these results show that prescription 
rates to children with negative test results at the six hos-
pitals did not correlate with reported endemicity levels at 
respective sites, implying that other factors, such as qual-
ifications, beliefs, and attitudes of health workers were 
likely in play [18]. Regardless of variation in practice, and 
Table 3 Covariates associated with prescription of an anti-malarial drug among children with only negative malaria tests 
results
Clustering on the day of admission adjusted using GEE
a History of fever or elevated temperature
b History of or witnessed convulsions, altered consciousness, tea coloured urine, jaundice, unconsciousness, lethargy, inability to sit, or severe pallor
Covariates Proportion prescribed  
an antimalarial (%)
Univariate analysis Multivariate analysis
OR 95 % CI p value aOR 95 % CI p value
Hospital
 Kabale 513/3544 (14.5) Reference Reference
 Tororo 1154/5541 (20.8) 1.55 1.39-1.74 <0.001 1.72 1.44-2.04 <0.001
 Apac 814/2841 (28.7) 2.37 2.10-2.69 <0.001 2.69 2.23-3.24 <0.001
 Kambuga 877/2196 (39.9) 3.93 3.46-4.46 <0.001 3.39 2.88-4.00 <0.001
 Jinja 5661/10,571 (53.6) 6.81 6.16-7.54 <0.001 7.45 6.37-8.71 <0.001
 Mubende 2958/5517 (53.6) 6.83 6.13-7.60 <0.001 7.19 6.17-8.39 <0.001
Age
 <6 months 692/4062 (17.0) Reference Reference
 6–12 months 2440/6272 (38.9) 3.10 2.82–3.41 <0.001 3.82 3.43–4.26 <0.001
 ≥12 months 8840/19,866 (44.5) 3.90 3.58–4.26 <0.001 4.89 4.45–5.41 <0.001
Fevera
 Absent 487/3982 (12.2) Reference Reference
 Present 11,490/26,216 (43.8) 5.60 5.08–6.18 <0.001 5.41 4.86–6.02 <0.001
Clinical findings suggestive of complicated malariab
 Absent 4329/14,819 (29.2) Reference Reference
 Present 7648/15,391 (49.7) 2.39 2.28–2.51 <0.001 1.94 1.83–2.06 <0.001
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for as long as laboratory test results are credible, as was 
the case in the settings where this study was conducted, 
prescribing anti-malarials to children with negative test 
results is wasteful, puts patients at risk of harmful effects 
of medicines, and may promote drug resistance [12, 16, 
27, 28]. Furthermore, amidst procurement and supply 
challenges, sustaining supply of intravenous artesunate 
cannot be guaranteed amidst the indiscriminate pre-
scription of anti-malarials [24, 25, 29, 30]. Finally, diag-
nosing and treating children with negative malaria test 
results can erode health worker confidence in otherwise 
effective medicines, miss other serious causes of febrile 
illness, and contribute to poor outcomes, including a 
possible increase in mortality [12, 19, 26, 31]. It should be 
noted that while the rate of anti-malarial prescription to 
children with a negative malaria test was high at the hos-
pitals involved in this study, it does compare favorably to 
rates published at other Ugandan hospitals [32, 33], likely 
reflecting the influence of UMSP training efforts.
Key to lowering the rate of prescription of anti-malar-
ials to children with negative test results will be a bet-
ter understanding of factors associated with this case 
management decision, and the results suggest possible 
reasons for this practice. With limited clinical skills and 
diagnostic capacity to evaluate patients, clinicians are 
unable to confirm alternate diagnoses and often disregard 
negative test results. Presented data support this hypoth-
esis—children presenting with signs and symptoms simi-
lar to those of complicated malaria, such as pallor, and 
histories of fever, convulsions, and passing tea coloured 
urine were more likely to be prescribed anti-malarials 
after a negative test than children who did not have these 
findings. Additional evidence in support of this hypoth-
esis is that the magnitude of association between study 
sites and anti-malarial prescription among children with 
negative test results doubled upon regression analysis 
limited to children with clinical findings suggestive of 
complicated malaria, as compared to analysis limited to 
those without clinical findings suggestive of complicated 
malaria. In addition, qualitative research work has shown 
that health worker beliefs towards perceived benefits of 
anti-malarial treatment are often overrated superseding 
rational clinical judgment. This behaviour is likely influ-
enced by promotion of malaria as an important disease 
[34], peer pressure and patient demand for anti-malarial 
drugs which are often available at most health facilities 
[31, 35, 36], encouraging clinicians to treat malaria even 
in  situations where malaria is unlikely [37]. In as much 
as prescription of anti-malarial to children with nega-
tive results is irrational, circumstances may exist when 
the practice is justified. For example, it may be reason-
able to prescribe anti-malarials to someone who tested 
negative but was admitted after therapy had already been 
initiated at another health facility. Additionally, long 
turnaround times for test results warrant starting therapy 
before the test results are available. Importantly, the find-
ings demonstrate the importance of repeating a negative 
test result when in doubt, as even in the study setting a 
small proportion of children who were initially negative 
became positive upon repeat testing.
This study had some limitations. First, it is possible that 
some treatments documented on the MRF were never 
administered and others were administered without doc-
umentation. Additionally, study data came from a malaria 
sentinel surveillance site programme and may not reflect 
what is happening at other public hospitals in Uganda. 
Furthermore, classification of those with malaria was 
limited to diagnostic testing results and it was not pos-
sible to ascertain where patients fell on the spectrum of 
disease from asymptomatic parasitaemia to complicated 
malaria. Lastly, data on treatment prior to hospitalization 
was not captured, which may have influenced some cli-
nicians to prescribe anti-malarials even when test results 
were negative.
Conclusions
Demonstrated is that the practice of irrational prescrip-
tion of anti-malarials remained high at six hospitals serv-
ing as malaria sentinel sites. These findings are of concern 
considering that Uganda changed policy to laboratory 
based confirmation, and that testing rates were high in 
the hospitals where the study was done, implying that the 
situation could be more serious in government hospitals 
where opportunities for testing, training and supervi-
sion are not comparable. Given this, it will continue to be 
extremely challenging to implement the WHO test and 
treat policy in Uganda and similar settings [37]. Sustained 
interventions targeted towards strengthening diagnos-
tic and treatment capacity for malaria and non-malaria 
febrile disease, and changing health worker beliefs and 
attitudes towards malaria diagnosis are required. Behav-
iour change can be achieved through implementation of 
standard training programmes integrated into vigorous 
evaluation, supervision, and mentorship systems.
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